This is a repository copy of STAAR: a randomised controlled trial of electronic adherence monitoring with reminder alarms and feedback to improve clinical outcomes for children with asthma.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/116628/

Version: Accepted Version

Article:

https://doi.org/10.1136/thoraxjnl-2015-208171

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
STAAR: a randomised controlled trial of electronic adherence monitoring with reminder alarms and feedback to improve clinical outcomes for children with asthma.

Corresponding author: Robert Morton
Sheffield Children’s Hospital
Western Bank, Sheffield, S10 2TH, United Kingdom
rwmorton99@gmail.com
Tel. 07968788032

Robert W Morton¹,², Heather E Elphick¹,², Alan S Rigby³, William J Daw¹,², David A King¹, Laurie J Smith², Mark L Everard⁴

¹ Academic Unit of Child Health, University of Sheffield, Sheffield, UK
² Department of Respiratory Medicine, Sheffield Children’s Hospital, Sheffield, UK
³ Hull York Medical School, University of Hull, Hull, UK
⁴ School of Paediatrics and Child Health, Princess Margaret Hospital University of Western Australia, Perth, Australia

Key words: Paediatrics, Asthma, Adherence, feedback, exacerbations
Word Count: 3541
Abstract

Background

Sub-optimal adherence to inhaled steroids is common in children with asthma and is associated with poor disease control, reduced quality of life and even death. Previous studies using feedback of electronically monitored adherence data have demonstrated improved adherence but have not demonstrated a significant impact on clinical outcomes. The aim of this study was to determine whether introduction of this approach into routine practice would result in improved clinical outcomes.

Methods

Children with asthma aged 6-16 years were randomised to the active intervention consisting of electronic adherence monitoring with daily reminder alarms together with feedback in the clinic regarding their inhaled corticosteroid use or to the usual care arm with adherence monitoring alone. All children had poorly controlled asthma at baseline, taking inhaled corticosteroids (ICS) and long acting beta agonists (LABAs). Subjects were seen in routine clinics every three months for one year. The primary outcome was the Asthma Control Questionnaire (ACQ) score. Secondary outcomes included adherence and markers of asthma morbidity.

Results

77 of 90 children completed the study (39 intervention, 38 control). Adherence in the intervention group was 70%, vs 49% in the control group (p = <0.001). There was no significant difference in the change in ACQ but children in the intervention group required significantly fewer courses of oral steroids (p= 0.008) and fewer hospital admissions (p= <0.001).

Conclusion

The results indicate that electronic adherence monitoring with feedback is likely to be of significant benefit in the routine management of poorly controlled asthmatic subjects.
What is the key question?

Can electronic adherence monitoring with feedback and alarms improve clinical outcomes in children with poorly controlled asthma?

What is the bottom line?

Electronic monitoring with feedback and alarms improved adherence, decreased hospital admissions and courses of oral steroids required.

Why read on?

This study provides the first unequivocal evidence that adherence monitoring with feedback can impact on important clinical outcomes when used in the management of children with poorly controlled asthma.

Twitter

Electronic adherence monitoring with feedback and alarms can be effectively used in the clinical setting to improve clinical outcomes for children with asthma.
INTRODUCTION

Adherence to inhaled steroids is often sub-optimal in children with asthma, resulting in poor disease control, increased need for oral steroids and decreased lung function. This leads to increased healthcare utilisation, and associated cost. The recent National Review of Asthma Deaths in the UK reported that poor adherence was associated with 34% of deaths due to asthma, emphasising the significance of the problem.

Large adult population studies, and smaller paediatric studies have shown that adherence rates of 75-80% are required to significantly improve asthma control. However, when objectively measured, the average rate of adherence in children with asthma is around 50%, some way below this desired therapeutic level.

Subjective and indirect measurements of adherence have been shown to over-estimate rates due to patients wanting to be looked upon favourably by their clinician - the social desirability bias. Electronic monitoring devices (EMDs) record adherence rates by logging the exact date and time an inhaler is actuated, with modern devices proven to be highly accurate and reliable in the clinical setting. Monitoring allows intentional adherence barriers such as negative illness perceptions or medication beliefs to be identified, and addressed with regular open dialogue. Reminder alarms built into the devices can address non-intentional practical barriers such as simply forgetting to take the medication.

Due to their cost, the British Thoracic Society (BTS) has questioned the viability of EMDs outside the research setting, and The National Institute of Health and Excellence (NICE) has recommended further studies to investigate their use clinically.

An Australian study demonstrated that children’s adherence increased when electronic data was fed back, although it was under-powered to show any improvement in clinical outcomes. A recent study in New Zealand improved self-reported asthma control in the short-term using electronic monitoring, no feedback and reminder alarms. However, this study involved seeing subjects out of clinic every 2 months, used covert monitoring, and had no effect on objective clinical outcomes.

In order to determine whether clinically relevant benefits could be observed in a routine clinical setting through the use of electronic monitoring we undertook a study in which children with poorly controlled asthma were randomised to the use of reminder alarms and feedback or routine care.
We hypothesized that by addressing both the intentional and non-intentional adherence barriers, rates would increase to a degree necessary to improve asthma control and clinical outcomes.
METHODS

The STAAR study (STudy of Asthma Adherence Reminders) was a multi-centre, open label, parallel group randomised controlled trial, with an allocation ratio of 1:1. Written consent was taken from the parents/ carers of all participants, and ethical approval for the study was granted by the South Yorkshire Research Ethics committee, REC reference 13/YH/0289. The protocol was registered with ClinicalTrials.gov, number NCT02451709.

Participants & setting

Children with doctor-diagnosed asthma aged 6-16 years attending clinics in Sheffield or Rotherham were screened for eligibility. Participants had to be taking regular inhaled steroids, with no change in their medication in the last month. At recruitment, participants had to have an Asthma Control Questionnaire (ACQ) score of at least 1.5, indicating they had poorly controlled asthma. Participants were excluded if they couldn’t speak English, or if they had another significant chronic condition. The EMDs available for this trial were only compatible with seretide or symbicort inhalers. Therefore all participants were at BTS level 3 at the start of the trial.

Interventions

Prior to randomisation, all participants had their inhaler technique checked by a qualified asthma nurse, and received a brief asthma education session, emphasizing the importance of taking inhaled steroids regularly. All participants were seen in their standard asthma clinics 3 monthly and all treatment decisions were made by the clinical team. A member of the study team downloaded data from the EMD at each visit.

Intervention Group

Participants in the intervention group had an EMD attached to their regular inhaler. The devices used in this study were “Smartinhalers” and “Smartturbos”, manufactured by Adherium, [Auckland, New Zealand] (figure 1). The EMDs are commercially available, have a CE safety mark, and are validated for adherence monitoring in asthma. Participants were told the devices monitored the date and time of all actuations. At clinic visits, the adherence data from the previous 3 months was uploaded to the website www.smartinhalerlive.com, which displays the data graphically. These data were reviewed with the patient and parent/ carer (figure 2). Open, non-judgemental discussions were held about the adherence rate, barriers identified and, if necessary, personalised strategies for improvement were devised. Devices were set to play reminder alarms (children’s music or character noises), with different times agreed for weekdays and weekends. Alarms sounded for 5 seconds,
every minute for 15 minutes (or until actuation) if the inhaler hadn’t been actuated within the previous 6 hours of the specified time. The devices were locked to prevent tampering. Times were reviewed each study visit and changed if necessary. An example was a child who missed evening doses due to Arabic classes, therefore alarms were changed to later in the evening on weekdays.

Control Group

Control participants had the same EMDs attached to their regular inhaler, they were also told the devices monitored how much the inhalers were taken, but that these data would not be reviewed. Participants were seen in their standard asthma clinic and the data was downloaded, but not reviewed. The alarms were disabled, and the devices locked.

Primary Outcome

The primary outcome for the study was change in the ACQ score at 3, 6, 9 and 12 months. The ACQ is a questionnaire validated for the use in children aged 6-16\(^{22}\). There are 6 clinical questions related to symptoms in the previous week, and the 7\(^{th}\) score corresponds to the Forced Expiratory Volume in one second, per cent predicted (FEV1\%). A mean of the 7 values is calculated, giving a score of 0-6, with a higher score indicating more poorly controlled asthma.

Secondary Outcomes

Secondary outcomes recorded at baseline and each visit were FEV1\%\(^{23}\), number of unplanned attendances to GP/ED for asthma since last visit (as reported by parents), number of \(\beta\)-agonists in the past week and BTS level of asthma therapy. Quality of life was measured using the Mini Paediatric Asthma Quality of Life Questionnaire (mini PAQLQ\(^{24}\)). The adherence rate was calculated for each 3 month period, both morning and afternoon doses, and recorded as a percentage. This was calculated as number of doses actually taken/ number of doses prescribed x 100. The daily adherence was capped at 100%, to avoid falsely increased values due to dose dumping. The overall 3 monthly figure was a mean of each daily %. Parental beliefs about inhaled steroids and perceptions about asthma were recorded at baseline and 12 months with the Beliefs about medicines questionnaire (BMQ) and the Brief Illness Perceptions Questionnaire (IPQ\(^{25}, 26\)).

Sample Size

The sample size was calculated using a repeated measures analysis for 4 follow-up visits. The Minimal Clinically Important Difference (MID) for the ACQ is 0.5\(^{22}\). Using a repeat measure analysis
table we calculated for a significance of 5% (\( \alpha = 0.05 \)), and a power of 80%, with a repeated measure correlation of 0.4, that \( n = 76 \). To allow for a 15% attrition rate we aimed to recruit 90 participants to the study.

**Randomisation**

Participants were randomised using permuted block randomisation, with an allocation of 1:1, which resulted in equal group sizes of 45, created from a computer generated random number sequence. The allocation of subjects following recruitment involved phoning the independent holder of the randomisation code.

**Blinding**

Due to the nature of the intervention, neither the participants nor the study team were blinded in this study. In the intervention group adherence data was made available to clinicians if requested, but not in the control group.

**Statistical analysis**

The ACQ and FEV1\% were compared statistically by two approaches. First, by calculating a paired difference between 12-months and baseline for each group separately. The ‘difference of the difference’ between treatments was compared by an independent t-test. A 95% confidence interval was calculated. Second, an area under the curve (AUC) was calculated for each group and the between-group difference was determined by an independent t-test. The AUC is a mean value weighted by time. An arbitrary level of 5% statistical difference was assumed (two-tailed). Incident rates were estimated by Poisson regression, and compared by incident rate ratios (IRRs). The assumption of Poisson regression (mean=variance) was confirmed. Continuously distributed data was summarised by the median (quartiles); categorical data by n (%). A sensitivity analysis was carried out on the primary outcome measure (ACQ) using multiple imputation (MI). The approach used is detailed in appendix 1, with charts demonstrating the patterns for missing data. The “Stata” statistical computer package was used for data analysis.

**RESULTS**

90 children (81 Sheffield, 9 Rotherham) were recruited between October 2013 and August 2014, figure 3 shows the flow of these participants.
Baseline characteristics

The baseline characteristics are shown in table 1.

<table>
<thead>
<tr>
<th></th>
<th>Intervention group (n=47)</th>
<th>Control group (n=42)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age [years]</strong></td>
<td>10.4 (2.9)</td>
<td>10.2 (2.9)</td>
</tr>
<tr>
<td><strong>Sex male</strong></td>
<td>28(60%)</td>
<td>22(52%)</td>
</tr>
<tr>
<td><strong>ACQ</strong></td>
<td>2.5(0.8)</td>
<td>2.3(0.7)</td>
</tr>
<tr>
<td><strong>FEV1 %</strong></td>
<td>87.2 (14.9)</td>
<td>88.0 (13.4)</td>
</tr>
<tr>
<td><strong>PQL</strong></td>
<td>4.3(1.5)</td>
<td>4.6(1.2)</td>
</tr>
<tr>
<td><strong>ICS dose</strong></td>
<td>697.9(348.6)</td>
<td>664.3(280.1)</td>
</tr>
<tr>
<td><strong>BTS</strong></td>
<td>3.5(0.6)</td>
<td>3.4(0.5)</td>
</tr>
<tr>
<td><strong>Proportion BTS ≥ 4</strong></td>
<td>51%</td>
<td>43%</td>
</tr>
<tr>
<td><strong>GP/ED visits</strong></td>
<td>1.9(2.2)</td>
<td>2.1(2.0)</td>
</tr>
<tr>
<td><strong>Beta agonist</strong></td>
<td>2.5(1.3)</td>
<td>2.3(1.3)</td>
</tr>
<tr>
<td><strong>School days missed</strong></td>
<td>3.5(4.4)</td>
<td>3.8(5.7)</td>
</tr>
<tr>
<td><strong>Oral steroids</strong></td>
<td>1.2(1.8)</td>
<td>1.2(1.3)</td>
</tr>
<tr>
<td><strong>Hospital admissions</strong></td>
<td>0.3(0.6)</td>
<td>0.2(0.6)</td>
</tr>
<tr>
<td><strong>BMQ score</strong></td>
<td>2.5 (0.5)</td>
<td>2.6 (0.4)</td>
</tr>
<tr>
<td><strong>IPQ score</strong></td>
<td>5.6 (1.3)</td>
<td>5.3 (0.9)</td>
</tr>
<tr>
<td><strong>Ethnicity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WB</td>
<td>30(64%)</td>
<td>24(57%)</td>
</tr>
<tr>
<td>BA</td>
<td>3(6%)</td>
<td>6(14%)</td>
</tr>
<tr>
<td>BP</td>
<td>11(23%)</td>
<td>11(26%)</td>
</tr>
<tr>
<td>BI</td>
<td>0(0%)</td>
<td>1(2%)</td>
</tr>
<tr>
<td>AO</td>
<td>1(2%)</td>
<td>0(0%)</td>
</tr>
<tr>
<td>BC</td>
<td>2(4%)</td>
<td>0(0%)</td>
</tr>
<tr>
<td><strong>Time from asthma diagnosis (years)</strong></td>
<td>6.0 (3.7)</td>
<td>6.7 (3.7)</td>
</tr>
</tbody>
</table>

Table 1 – Baseline data. Data are mean (SD)or n (%). Notes. Calculations subject to rounding errors. ACQ=asthma control questionnaire. FEV1%= Forced expiratory volume in 1 second, % predicted. PQL=paediatric quality of life questionnaire. ICS dose = beclometasone equivalent. Beta agonist use – score on ACQ question. WB=white British, BA=black African, BP=British Pakistani, BI=British Indian, AO=Asian other, BC=black Caribbean. GP/ED visits, school days missed, oral steroids required and hospital admissions are all parent reported events over the previous 3 months.
Primary Outcome

The ACQ decreased in both groups between the baseline and the 3-month visit. It fell by 1.0 in the control group and 0.9 in the intervention group (p=0.35), both significantly exceeding the MID for changes in ACQ scores of 0.5. This improvement was maintained to 12 months in both treatments arms (figure 4). At 12 months there were no significant differences between the two groups for either the mean change from baseline (table2) or the areas under the curve (table 3). The individual participant trajectories for ACQ across the study visits are shown in appendix 1 (figure A3).

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Intervention baseline</th>
<th>Intervention 12 months</th>
<th>Paired mean difference</th>
<th>Control baseline</th>
<th>Control 12 months</th>
<th>Paired mean difference</th>
<th>Difference of the difference</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACQ</td>
<td>2.65 (0.12)</td>
<td>1.58 (0.19)</td>
<td>-1.14 (0.21)</td>
<td>2.47 (0.12)</td>
<td>1.50 (1.07)</td>
<td>-0.95 (0.77)</td>
<td>-0.18 (0.28)</td>
<td>-0.76,0.38</td>
<td>0.51</td>
</tr>
<tr>
<td>FEV1%</td>
<td>87.23 (2.77)</td>
<td>91.37 (1.33)</td>
<td>3.00 (1.67)</td>
<td>88.00 (1.07)</td>
<td>88.97 (2.55)</td>
<td>1.54 (2.18)</td>
<td>1.45 (3.68)</td>
<td>-4.00,6.91</td>
<td>0.59</td>
</tr>
</tbody>
</table>

Table 2. Outcome measures for ACQ and FEV1%. Data are means (SD in parentheses). The difference of the difference is an estimative statistic where the SD has limited value.

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Control</th>
<th>Difference</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.7 (0.13)</td>
<td>1.6 (0.14)</td>
<td>0.09 (0.18)</td>
<td>(-0.26,0.45)</td>
<td>0.52</td>
</tr>
</tbody>
</table>

Table 3 – Comparison of areas under the curve for ACQ

Secondary Outcomes

Average adherence over the 12 months for the intervention group was 70%, vs. 49% for the control group (p=<0.001). Higher mean and median adherence rates were maintained for the 12 month period in the intervention group, but declined over time in the control group (figure 5). 20 Participants in the intervention group, and 6 in the control group had a mean adherence rate of >80% for the 12 month period. 4 participants in the intervention group and 11 in the control group had rates of <30%.

Event rates are shown in table 4. The mean (SD) days in study was 351 (117) days for the intervention group, and 358 (101) days for the control group. Figure 5 shows the timing of rescue oral steroids required during the study.
<table>
<thead>
<tr>
<th>Event rate (per 100 child days)</th>
<th>P value</th>
<th>IRR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intervention</strong></td>
<td><strong>Control</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GP/ED visits (n=193)</td>
<td>0.582</td>
<td>0.650</td>
<td>0.316</td>
</tr>
<tr>
<td>Days off school due to asthma (n=462)</td>
<td>1.365</td>
<td>1.606</td>
<td>0.1</td>
</tr>
<tr>
<td>Courses of oral steroids (n=156)</td>
<td>0.411</td>
<td>0.676</td>
<td>0.008</td>
</tr>
<tr>
<td>Hospital admissions (n=20)</td>
<td>0.0254</td>
<td>0.129</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

**Table 4 Incident rates for clinical outcomes.** n = total number of events in study as reported by parents. IRR = Incident Rate Ratio. CI = Confidence Interval. Example interpretation: controls are 53% more likely to be prescribed steroids than those in the intervention.

There were no significant differences between the two groups for short acting β-agonist use, change in BTS stage, mini PAQLQ, BMQ or IPQ scores. FEV1% improved in both treatment arms, with no significant difference between treatments at 12-months compared to baseline (table 2). The mean (SD) beclometasone equivalent ICS dose at the end of the study was 673 (303) mcg in the intervention group, and 767 (369) mcg in the control group.

**Clinic visits**

Patients did not attend (DNA) or cancelled 143 scheduled appointments (73 intervention, 66 control). Appointments were re-scheduled, but where this was not possible, 35 non-clinical study visits (15 intervention, 20 control) were performed. As a result of these missed study visits, only 41% of participants in the intervention group received feedback at all three time points (3, 6 & 9 months). Missing data for ACQ and adherence is shown in tabulated form in Appendix 1.
Issues with electronic adherence monitors

Table 5 shows the frequency of devices lost, forgotten or broken. Missed data from forgotten devices was downloaded at a later clinic appointment. Table 5 shows the number of broken, forgotten, and lost devices. Reasons given for being damaged (just reported, or actually broken) included lost/flat battery, dropped on floor, dropped in liquid, alarms not starting, alarms not stopping, screens peeled off.

<table>
<thead>
<tr>
<th>Reason</th>
<th>Intervention (47 participants)</th>
<th>Control (42 participants)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Device reported as “broken” by child</td>
<td>23 (50%)</td>
<td>8 (19%)</td>
</tr>
<tr>
<td>Devices damaged beyond repair,</td>
<td>17 (37%)</td>
<td>2 (5%)</td>
</tr>
<tr>
<td>(when inspected by study team,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>requiring replacement device)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participant forgot to bring device</td>
<td>10 (22%)</td>
<td>18 (43%)</td>
</tr>
<tr>
<td>to clinic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Device lost completely</td>
<td>5 (11%)</td>
<td>2 (5%)</td>
</tr>
</tbody>
</table>

Table 5: Broken, forgotten and lost devices
DISCUSSION

While use of electronic adherence monitoring with feedback and regular alarms by children with poorly controlled asthma did not significantly improve self-reported asthma control, there was a significant increase in adherence rates that was maintained over the 12 months. This improvement was associated with a significant decrease in the number of exacerbations requiring a course of oral steroids or an admission to hospital. This is the first study to our knowledge that has shown that regular alarms and feedback of electronic adherence data has a significant effect on a number of clinically relevant outcomes. Importantly, the intervention was built into routine clinical care and the benefits were sustained over the 12 month study period.

Previous studies using this approach have also demonstrated improved adherence through the use of reminders with or without feedback, but they have failed to demonstrate a significant difference in clinical outcomes. These studies have variously involved relatively well controlled and adherent subjects \(^{29}\), relatively mild asthmatic subjects managed in the community \(^{30}\), or have been too small to demonstrate significant difference \(^{19}\). In this study the subjects all had ‘poorly controlled asthma’ (ACQ \(\geq 1.5\)), and hence there was possibly greater potential to have an impact than those included in previous studies. Our results are consistent with the study of Williams et al., who in a study of 298 adults with asthma found that patients with an adherence in excess of 75%, as assessed by pharmacy records, were significantly less likely to require an ED visit, a course of oral steroids or a hospital admission \(^{6}\).

The results from this study suggest that this approach is likely to be beneficial if introduced into routine clinical care, at least in those children with poor asthma control. It is likely that the intervention resulted in an overall reduction in health costs, given that the majority of the direct costs associated with asthma are attributable to hospital admissions, or exacerbations sufficient to require intervention \(^{31}\). In this study the hospitalisation rate was five times higher in the control group despite self-reported symptoms being similar. This approximates to the prevention of 12 hospitalisations in one year amongst the 47 intervention subjects giving an approximate figure for the number to treat of 3.25. There would appear to be a cost saving in using this approach, even at current prices (£120 per device). The BTS questioned the utility of this approach due to high device cost, but its introduction into routine practice would reduce unit price, as it would drive competition and innovation.

Adherence in the control group fell progressively over the year, consistent with results from previous studies \(^{29,30,32}\). At 49% the median adherence was similar to the value of 53% derived from our
analysis of 18 previous studies using electronic monitors to quantify adherence rates in children. In contrast, the intervention group maintained a significantly higher level of adherence throughout the study and this was associated with the important improvements in clinical outcomes. Whilst both groups required fewer courses of oral steroids during the study compared to baseline rates, significantly more courses were required in the control group throughout. This difference between groups was more marked at nine and twelve months, with rates increasing in the control group in the second six months (figure 6). Similar patterns of increasing control group rates in the second six months were seen for hospital admissions, days off school and GP/ED visits. This would suggest the benefit of this intervention was over a prolonged period of time, maintaining increased adherence rates with regular feedback and discussion.

Which part of the intervention had the greatest impact is unclear. A previous study found reminders alone can have an impact on adherence but this was in a self-selecting group of well controlled adult subjects whose mean adherence was high (74%) in the control group. It is likely that the feedback in this study played a major role in sustaining improved adherence rates, since other studies using reminders alone have observed declining adherence over time. Burgess et al also reported sustained improvements in adherence over time through feedback though the study only ran for 4 months and subjects were seen every 4 weeks. Accurate electronic data that could be discussed with the family appeared to facilitate an open and honest discussion about adherence and the barriers encountered, leading to evolving practical solutions. Social-desirability could be used in a positive way to influence medication taking behaviour. However, for some participants the interventions did not appear to impact on adherence and there were a disproportionate number in this group who reported damaged or lost devices. This approach may not fully address the issue of intentional non-adherence, but it does help to confirm the problem, should the devices remain operational.

In support of the argument that feedback and discussion are important are the results from a recent study which demonstrated that in 220 children, despite improving self-reported asthma control, electronic monitoring and alarms had no effect on objective clinical outcomes. Subjects were seen out of clinic every 2 months for 6 months, with adherence declining at each time point in both groups, possibly leading to the initial impact on exacerbations disappearing beyond 2 months. Importantly the participants received no direct feedback, preventing the opportunity to initiate an open dialogue. Moreover, covert adherence monitoring was used, an approach that cannot be recommended in routine practice.
Out of necessity this was an open label study. The risk of introducing an inadvertent bias was minimised by ensuring both groups had the same number of clinic visits (136 intervention, 124 control) and ensuring clinical management was undertaken by the patients’ usual clinicians. The control participants were aware that their adherence was being monitored in a clinical trial, and the increased rates seen at 3 months may be due to this. It is possible that true adherence was lower in the intervention group than that recorded as the devices (and all EMDs currently available) simply recorded actuations with no guarantee the medication was inhaled. Participants or family members could have potentially pressed the device randomly, or to silence alarms. Future devices are likely to overcome this problem by detecting inhalation using thermistors or other air flow monitors, an approach used successfully in electronic respiratory rate monitors.

The lack of difference in ACQ in the two groups despite what appear to be significant differences in adherence rates is consistent with results reported in other studies. Similarly recent community studies have reported a disconnect between self-reported symptoms and other clinical outcomes such as exacerbation. This is possibly because the ACQ score is a subjective measure. Open, honest dialogue facilitated by adherence discussions may have made children more honest about the severity of their symptoms in the intervention group. In contrast, answers from control subjects may have been more guarded, with denial of symptoms, as is the case in standard clinical practice, particularly in adolescents. Additionally patients who knew their adherence has been poor may have minimised symptom reporting. The ACQ scores and FEV1% may also reflect short term influences such as the recent use of oral steroids, which was significantly more common in the control group. The lack of a significant difference in FEV1% between groups and poor correlation with exacerbations may be due to FEV1% being an inaccurate way of grading asthma severity in children.

This was designed to be a pragmatic study in which asthmatic children continued with usual care with or without the intervention. There was a high rate of participants cancelling appointments, or simply not attending. This appears to reflect the attitude of many patients and their families who don’t necessarily always consider asthma a significant condition. The overall DNA rate in this study was 20% (71/360 appointments, 38 group A, 33 group B), and this compares to a rate of 12% in respiratory clinics in Sheffield. This may demonstrate a reluctance to attend if the participant felt they may be judged or blamed for poor adherence by the study team or parent. Alternatively, due to their improved clinical condition (shown by improved ACQ), participants may have missed appointments because they felt better, a common reason for non-attendance. Related to this issue were the high levels of devices reported to be ‘broken’. Patel and colleagues reported a
Smartinhaler malfunction rate of 1.9%, and 3.5% lost when assessing 2642 monitors in an adult study. Our rates of malfunction and loss were much higher (35% and 8% respectively), suggesting some of the devices were deliberately broken or lost. The higher rates in the intervention group (50% broken, 11% lost) suggest that children are more likely to break or lose their device when their adherence is being openly monitored. The next generation of devices provide automated uploading of data via smartphones such that adherence can be monitored in real-time, which offers significant advantages in terms of logistics and opportunity to influence behaviour. These high rates of damage may suggest that this approach was disliked by the participants. However, the devices were popular and positive feedback was received, with the majority of participants asking to keep their device after the study period. A recent qualitative study to investigate young peoples’ opinions on electronic monitoring and feedback using these Smartinhaler devices also reported positive opinions, concluding that this is a popular intervention for both adolescents and their parents.

In summary, these data indicate that significant clinical benefits can be derived from using electronic adherence monitoring with feedback and alarms. A sustained improvement in adherence rates was associated with a decreased number of courses of oral steroids required and hospital admissions when used in a population of poorly controlled asthmatic children using combination therapy.

Acknowledgements

We would like to thank Dr Sonal Kansra, Dr Kelechi Ugonna, Dr Ruth O’Reilly and Dr Ben Bradbrook for accommodating the study in their asthma clinics. We would like to thank the specialist respiratory nurses Moira Gibbons, Nichola Butler, Anita Critchlow, Emma Sheppard and Bridget Howe for their help facilitating the study visits in clinic. We would like to thank the respiratory physiologists Karen O’Donnell and Royston Andrew for performing lung function on the participants. We would like to thank our independent pharmacist Jayne Clements for performing the
randomisation. Finally, we would like to thank Alexandra Spooner and all the other staff in R&D at Sheffield Children’s Hospital for implementing the study.

Conflicts of Interest
None

Funding
This study was funded by the Sheffield Children’s Hospital Charity

Contributorship Statement
RWM wrote the protocol for the study, applied for and secured ethical approval for the study, and applied for and secured funding for the study. He recruited participants, carried out study visits, recorded the results and wrote and edited the manuscript.

HEE helped write the protocol, helped apply for funding, supervised the implementation of the study, and helped write and edit the manuscript.

ASR helped write the protocol, performed all the statistical analysis for the study and helped write and edit the manuscript.

WJD carried out study visits and helped edit the manuscript.

DAK helped apply for ethical approval, helped apply for funding, recruited participants, carried out study visits and helped edit the manuscript.

LJS recorded and analysed the lung function for all the participants in the study and helped edit the manuscript.

MLE devised the concept of the study, wrote the protocol, and helped write and edit the manuscript.

Figure legends
Figure 1 – “Smartturbo” and “Smarttrack” electronic adherence monitors. Adherium, New Zealand

Figure 2 – Adherence review graph from [http://www.smartinhalerlive.com](http://www.smartinhalerlive.com). The number of daily doses taken is the y axis, with the date on the x axis. In this example the participant was prescribed 4 doses on the first date, but only took 2.

Figure 3 – CONSORT 2010 flow diagram showing progress of participants through trial
Figure 4 – Box and whisker plot showing median ACQ scores over time for groups A (intervention) and B (control)

Figure 5 – Box and whisker plot showing median adherence rates over time for groups A (intervention) and B (control)

Figure 6 – Bar chart demonstrating the number of courses of oral steroids required for different time periods during the study for groups A (intervention) and B (control). Group A total 65 courses, Group B total 91 courses
References


15. Everard ML. The Emperor's New Clothes II--time for regulators to wake up and take responsibility for unnecessary asthma morbidity: time for the second aerosol 'transition'. Thorax 2013;68:891-3.


40. Howard S LA, Yule C. Exploring the attitudes of adolescents with asthma towards monitoring and sharing of data on their inhaler use. European Respiratory Journal 2015;46 (supplement 59).